Exhibit10.1

LOANPURCHASEANDSALEAGREEMENT (COMMERCIAL LOAN)

DatedandEffectiveasof June 5, 2026,

By and BetweenNEXBANKCAPITAL,INC.

astheSeller, and

NEXPOINTRESIDENTIALTRUSTOPERATINGPARTNERSHIP,L.P.

asthePurchaser.

---

LoanPurchaseandSaleAgreement(26E24)

---

LoanPurchaseandSaleAgreement(NCI-NXRT2605-S)

Pageof23

This LOAN PURCHASE AND SALE AGREEMENT (the “Agreement”), is entered into and effective on and as of June 5, 2026 (the “Effective Date”), by and between NEXBANK CAPITAL INC., a Texas corporation (the “Seller”) and NexPoint Residential Trust Operating Partnership, L.P., a Delaware limited partnership (the “Purchaser”).

WHEREAS, the Seller is the sole owner, record holder, and administrative agent of the Loan identified in the Loan Schedule appended as Schedule Ato the Purchase Confirmation.

…

SMARTRENT, INC.

2021 EMPLOYEE STOCK PURCHASE PLAN

(Amended and Restated May 12, 2026)

---

TABLE OF CONTENTS

Page

1.	Establishment, Purpose and Term of Plan.	1
1.1	Establishment	1
1.2	Purpose	1
1.3	Term of Plan	1
2.	Definitions and Construction.	1
2.1	Definitions	1
2.2	Construction	6
3.	Administration.	6
3.1	Administration by the Committee	6
3.2	Authority of Officers	7

…

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

| |

…

Amendment 1

to the License and Supply Agreement

between

Medac Gesellschaft für klinische Spezialpräparate m.b.H., a company duly organised and existing under the laws of Germany, having its head office at Theaterstraße 6, 22880 Wedel, Germany, registered with the commercial register of the local court of Pinneberg under HRB 12042 PI, VAT No. DE 118579535,

- “medac” -

and

UroGen Pharma Ltd, a company organized and existing under the laws of the State of Israel having an address at 9 HaTaassiya St., Ra’anana 4365405, Israel

- “UroGen” -

-hereinafter individually referred to as a “Party“ and collectively as the “Parties“-

The Parties executed a certain License and Supply Agreement, effective as of 16. January 2024 (the “Agreement”). The Parties desire to supplement the terms and conditions of the Agreement in order to define long-term storage activities for validation batches of the Product by medac. Unless otherwise specified, capitalized words set forth herein shall have the same meanings as defined in the Agreement.

…

AMENDED AND RESTATED DISTRIBUTION REINVESTMENT PLAN

OF

TRINITY CAPITAL INC.

Effective as of July 27, 2026

Trinity Capital Inc., a Maryland corporation (the “Company”), hereby adopts the following plan (the “Plan”) with respect to cash dividend distributions declared by its Board of Directors on shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”).

1. Unless a stockholder specifically elects to receive cash pursuant to paragraph 4 below, all cash dividend distributions hereafter declared by the Company’s Board of Directors shall be reinvested by the Company in the Company’s Common Stock on behalf of each stockholder, and no action shall be required on such stockholder’s part to receive such Common Stock.

2. Such cash dividend distributions shall be payable on such date or dates (each, a “Payment Date”) as may be fixed from time to time by the Board of Directors to stockholders of record at the close of business on the record date(s) established by the Board of Directors for the cash dividend distributions involved.

…

IMMUNEERING CORPORATION 2025 EMPLOYMENT INDUCEMENT AWARD PLAN

(As Amended June 11, 2026)

ARTICLE I.
PURPOSE

The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Plan are defined in Article XI.

ARTICLE II.
ELIGIBILITY

Eligible Individuals are eligible to be granted Awards under the Plan, subject to the limitations described herein.

ARTICLE III.
ADMINISTRATION AND DELEGATION

…

Employment Agreement

This Employment Agreement (this “Agreement”), dated as of June 10, 2026, is made by and between Immuneering Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Andrew Gengos (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective upon the date of last signature below and Executive’s commencement of employment with the Company on or before July 16, 2026 (the “EffectiveDate”).

RECITALS

A.It is the desire of the Company to assure itself of the services of Executive as of the Effective Date and thereafter by entering into this Agreement.

B.Executive and the Company mutually desire that Executive provide services to the Company on the terms herein provided.

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements set forth below, the Parties hereto agree as follows:

1.Employment.

…

NCR VOYIX CORPORATION

2026 STOCK INCENTIVE PLAN

ARTICLE I.

PURPOSE; DEFINITIONS

The purpose of the Plan is to give the Company a competitive advantage in attracting, retaining and motivating officers, employees, directors and consultants and to provide the Company and its Subsidiaries and Affiliates with an equity plan providing incentives directly linked to stockholder value.

Certain terms used herein have definitions given to them in the first place in which they are used. In addition, for purposes of the Plan, the following terms are defined as set forth below:

(a)    “Affiliate”means a corporation or other entity controlled by, controlling or under common control with, the Company.

(b)    “Applicable Exchange”means the New York Stock Exchange or such other securities exchange as may at the applicable time be the principal market for the Common Stock.

(c)    “Award”means an Option, SAR, Restricted Stock, Restricted Stock Unit, Other Stock-Based Award, or Cash Award granted pursuant to the terms of the Plan.

…

DINE BRANDS GLOBAL, INC.
2019 STOCK INCENTIVE PLAN
PERFORMANCE AWARD AGREEMENT

THIS PERFORMANCE AWARD AGREEMENT(the “Agreement”) is entered into as of June 15, 2026, by and between DINE BRANDS GLOBAL, INC., a Delaware corporation (the “Company”), and ___Lawrence Y. Kim , an employee of the Company (the “Participant”).

RECITALS:

Pursuant to the Dine Brands Global, Inc. 2019 Stock Incentive Plan (the “Plan”), the Compensation Committee of the Board of Directors of the Company (the “Committee”), as the administrator of the Plan, has determined that the Participant is to be granted a Performance Award (the “Award”) payable in the form of shares of the Company’s common stock, on the terms and conditions set forth herein.

Any capitalized terms not defined herein shall have their respective meanings set forth in the Plan.

AGREEMENT:

In consideration of the foregoing and of the mutual covenants set forth herein and other good and valuable consideration, the parties hereto agree as follows:

…

Rapport Therapeutics, INC.
SECOND AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

ThepurposeofthisSecond Amended and Restated Non-Employee DirectorCompensationPolicy (the “Policy”) of Rapport Therapeutics, Inc., a Delaware corporation (the“Company”),isto provideatotalcompensationpackagethatenablestheCompany toattractandretain,onalong-termbasis,high-caliberdirectorswhoarenotemployeesorofficersoftheCompany orits subsidiaries (“Outside Directors”). This Policy became effective on June 6, 2024 (the “Effective Date”). Infurtherance ofthepurpose statedabove,allOutside Directorsshallbe paid compensation for services provided to theCompanyas Outside Directors as set forth below:

Cash Retainers

AnnualRetainerforBoardMembership: $40,000 forgeneralavailabilityandparticipationin meetings andconferencecalls of ourBoard of Directors, to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter. No additional compensation will be paid for attending individual meetings of the Board of Directors.

…

KYMERA THERAPEUTICS, INC.

AMENDED AND RESTATED

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Kymera Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiary (“Outside Directors”). In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below:

Cash Retainers

Annual Retainer for Board Membership: $50,000 for general availability and participation in meetings and conference calls of our Board of Directors, to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter. No additional compensation will be paid for attending individual meetings of the Board of Directors.

…

SETTLEMENT AGREEMENT

THE UNDERSIGNED

1.

NewAmsterdam Pharma Company N.V., a private company with limited liability under Dutch law, having its corporate seat at Naarden and maintaining business premises at Gooimeer 2 35 in (1411 DC) Naarden, registered with the Chamber of Commerce under number 86649051, referred to hereafter as: the "Employer";

and

2.

Ms. L. (Louise) Kooij, residing at [***] (the "Employee");

each a "Party" and together, collectively, the "Parties".

WHEREAS

A.

The Employee has been employed by the Employer since 1 November 2022 on the basis of an employment agreement for indefinite term, pursuant to which the Employee was lastly employed in the position of Chief Accounting Officer (the "Employment Agreement").

B.

The Parties have different views on how the Employee's work should be conducted. The Parties have discussed their differences and came to the conclusion that a successful cooperation in the future is no longer feasible.

C.

…